Xencor (XNCR)
Biotech
Close on Nov 13, 2026 (from our latest Long View update): $37.09
- Market value
- $2.8Bat the Nov 13 close
- Revenue growth
- +34%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- −88%12 months to Sep 30, 2026 (10-Q)
- Net cash
- $556Mat Sep 30, 2026
- Worst fall since listing
- −87.0%Feb 8, 2021 to Aug 11, 2025; not back to that high (−36.9% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
Xencor has paid for its own pipeline mainly with partner payments, a 2023 sale of royalty rights and a 2024 share sale.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 16, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for Xencor, FY2012–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $109M in FY2016 to $126M in FY2025.
Free cash flow was positive in 3 of the 14 years shown; FY2025: −$138M.
Margins
Margins are not charted: in FY2025 the operating loss (−$178M) was larger than revenue ($126M). The table has each year's figures.
Diluted share count
The diluted share count rose 30% from FY2020 to FY2025, to 74M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $126M | — | −141% | −$92M | −$135M | $3M | −$138M |
| FY2024 | $110M | — | −161% | −$233M | −$202M | $6M | −$208M |
| FY2023 | $175M | — | −76% | −$133M | −$78M | $18M | −$96M |
| FY2022 | $165M | — | −50% | −$55M | $24M | $38M | −$14M |
| FY2021 | $275M | — | 16% | $83M | −$17M | $13M | −$30M |
| FY2020 | $123M | — | −63% | −$69M | −$5M | $11M | −$16M |
| FY2019 | $157M | — | 9% | $27M | $64M | $7M | $57M |
| FY2018 | $41M | — | −195% | −$70M | −$80M | $7M | −$87M |
| FY2017 | $46M | — | −93% | −$38M | −$34M | $5M | −$39M |
| FY2016 | $109M | — | 40% | $45M | $95M | $2M | $94M |
| FY2015 | — | — | — | −$18M | $27M | $2M | $25M |
| FY2014 | — | — | — | −$16M | −$21M | $0.8M | −$22M |
| FY2013 | — | — | — | −$60M | −$5M | $0.1M | −$6M |
| FY2012 | — | — | — | — | −$11M | $0.0M | −$11M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 74M | $611M | — | $43M | — | — |
| FY2024 | 65M | $707M | — | $53M | — | — |
| FY2023 | 61M | $697M | — | $54M | — | — |
| FY2022 | 60M | $584M | — | $49M | — | — |
| FY2021 | 60M | $598M | — | $37M | — | — |
| FY2020 | 57M | $599M | — | $32M | — | — |
| FY2019 | 58M | $601M | — | $32M | — | — |
| FY2018 | 54M | $530M | — | $21M | — | — |
| FY2017 | 47M | $363M | — | $14M | — | — |
| FY2016 | 42M | $403M | — | $8M | — | — |
| FY2015 | 39M | $193M | — | $5M | — | — |
| FY2014 | 31M | $55M | — | $2M | — | — |
| FY2013 | 16M | $78M | — | $0.2M | — | — |
| FY2012 | — | $2M | — | $0.0M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 16, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Diluted shares before FY2013 are left out: the earlier counts (before the company's listing or merger) are not comparable.
- Liabilities from the sale of future royalties are not counted as debt; the company reports them on their own line.
Returns by year
| Year | XNCR | S&P 500 |
|---|---|---|
| 2019 | −4.9% | +31.5% |
| 2020 | +26.9% | +18.4% |
| 2021 | −8.0% | +28.7% |
| 2022 | −35.1% | −18.1% |
| 2023 | −18.5% | +26.3% |
| 2024 | +8.2% | +25.0% |
| 2025 | −33.4% | +17.9% |
| 2026 to date | +122.1% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- VKTX Viking Therapeutics
- VERA Vera Down 1.2%
- SLS SELLAS Up 156.4%
- TNGX Tango Therapeutics Down 16.4%
- IOVA Iovance Down 35.4%
- NRIX Nurix Therapeutics Down 38.2%
Show all 17
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- ARWR Arrowhead Down 15.3%
- ORIC ORIC Pharmaceuticals Down 32%
- KRYS Krystal Down 11%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- ALNY Alnylam
- GMAB Genmab Up 28.3%
- MRNA Moderna Down 17.6%
Questions about Xencor
- How does Xencor make money?
- It sells no drugs of its own. It earns royalties and milestone payments from partners that use its XmAb antibody technology, among them Alexion (Ultomiris), Incyte (Monjuvi), Amgen, Astellas and Zenas, and it spends most of its money developing its own drug candidates. More in the Long View →
- Why doesn't Xencor keep all its royalties?
- In 2023 it sold rights to its Ultomiris and Monjuvi royalties to OMERS, a Canadian pension fund, for $215M upfront. Monjuvi royalties came back to Xencor when OMERS reached its $29.3M cap in 2026. OMERS is still entitled to up to $35M a year of Ultomiris royalties for 2026–28, and since the 2026 Alexion settlement Xencor must fund certain shortfalls in them. More in the Long View →
- What is XmAb819?
- Xencor's lead cancer drug candidate: an antibody that directs the immune system's T cells against kidney cancer cells carrying the protein ENPP3. Xencor plans to discuss accelerated approval (earlier approval based on a measure reasonably likely to predict benefit, with confirmatory trials required) with the FDA and, subject to regulatory feedback, to start a Phase 3 trial (a late-stage trial testing benefit and safety) against tivozanib by the end of 2027. More in the Long View →
- How does Xencor pay for its research?
- With partner payments, a 2023 sale of royalty rights, a 2024 share sale that raised $201.3M gross, and sales of shares it received from partners such as Zenas. It also has an unused $200M at-the-market share-sale agreement. More in the Long View →
- What's coming up for Xencor's pipeline in the next 12 months?
- Zenas BioPharma, which licensed obexelimab from Xencor and owes it milestones and royalties, says the FDA's target date for a decision on obexelimab in IgG4-related disease is May 27, 2027. As of Nov 4, 2026 More in the Long View →